Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol PR in Chronic Malignant Tumor-related Pain
NCT00505414Phase 3Terminated
- Sponsor
- Grünenthal GmbH
- Start
- Jun 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of tapentadol in cancer pain (3 arms), sponsored by Grünenthal GmbH. Primary endpoint: Responder Rates in Maintenance Period at Day 43. Started Jun 2007; status: terminated.
02
Drugs
tapentadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00505414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505414.